МЕТАБОЛИЧЕСКИЕ ЭФФЕКТЫ АДИПОНЕКТИНА
https://doi.org/10.15829/1728-8800-2014-6-68-72
Аннотация
Обсуждаются метаболические эффекты гормона адипонектина, его возможная роль в развитии метаболического синдрома, инсулинорезистентности, сахарного диабета 2 типа, атеросклероза, прогностические возможности адипонектина как маркера развития ишемической болезни сердца и будущих сердечно-сосудистых событий, терапевтические перспективы применения адипонектина.
Об авторах
Е. В. Митрошина
ГБОУ ВПО “Самарский государственный медицинский университет” Министерства здравоохранения Российской Федерации, Самара
Россия
д.м.н., проф., заведующий кафедрой эндокринологии
Россия
д.м.н., проф., заведующий кафедрой эндокринологии
А. Ф. Вербовой
ГБОУ ВПО “Самарский государственный медицинский университет” Министерства здравоохранения Российской Федерации, Самара
Россия
Россия
к.м.н., ассистент кафедры
Тел./факс: +7 (905) 303-02-70
Список литературы
1. Wang Y, Lau WB, Gao E, et al. Cardiomyocyte-derived adiponectin is biologically active in protecting against myocardial ischemia-reperfusion injury. Am J Physiol Endocrinol Metab. 2010; 298(3): E663-70.
2. Amin RH, Mathews ST, Alli A, et al. Endogenously produced adiponectin protects cardiomyocytes from hypertrophy by a PPARgamma-dependent autocrine mechanism. Am J Physiol Heart Circ Physiol 2010; 299(3): H690-8.
3. Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biological Chemistry 2004; 279 (13): 12152-62.
4. Ouedraogo R, Wu X, Xu SQ, et al. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. Diabetes 2006; 55(6): 1840-6.
5. Xu SQ, Mahadev K, Wu X, et al. Adiponectin protects against angiotensin II or tumor necrosis factor alpha-induced endothelial cell monolayer hyperpermeability: role of cAMP/PKA signaling. Arterioscler Thromb Vasc Biol 2008; 28(5): 899-905.
6. Shibata R, Sato K, Pimentel DR, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005; 11 (10): 1096-103.
7. Takemura Y, Ouchi N, Shibata R, et al. Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest 2007; 117 (2): 375-8.
8. Lau DC, Dhillon B, Yan H, et al. Adipokines: molecular links between obesity and atherosclerosis. American Journal of Physiology — Heart and Circulatory Physiology 2005; 288 (5): H2031-41.
9. Son BK, Akishita M, Iijima K, et al. Adiponectin antagonizes stimulatory effect of tumor necrosis factor-alpha on vascular smooth muscle cell calcification: regulation of growth arrest-specific gene 6-mediated survival pathway by adenosine 5’-monophosphate-activated protein kinase. Endocrinology 2008; 149 (4): 1646-53.
10. Takeuchi S, Wada K, Uozumi Y, et al. Adiponectin receptor 1 expression is associated with carotid plaque stability. Neurology India 2013; 61(3): 249-53.
11. Li S, Shin HJ, Ding EL, et al. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009; 302 (2): 179-88.
12. Karakas M, Zierer A, Herder C, et al. Leptin, adiponectin, their ratio and risk of Coronary Heart Disease: results from the MONICA/KORA Augsburg Study. 1984- 2002. Atherosclerosis 2010; 209 (1): 220-5.
13. Mitroshina EV. Interaction between adiponectin and lipid and carbohydrate metabolism in adolescents and men with puberty started obesity. University proceedings. Volga region. Medical sciences 2011; 2 (18): 11-8. Russian (Митрошина Е.В. Взаимосвязь уровней адипонектина с показателями липид- ного и углеводного обмена у юношей и мужчин с ожирением, манифестировав- шим в пубертатный период. Известия высших учебных заведений. Поволжский регион. Медицинские науки 2011; 2 (18): 11-8).
14. Kizer JR, Arnold AM, Benkeser D, et al. Total and high-molecular-weight adiponectin and risk of incident diabetes in older people. Diabetes Care 2012; 35(2): 415-23.
15. Butrova SA, Ershova EV, Ilyin AV, et al. Adiponectin in men with abdominal obesity. Obesity and metabolism 2006; 2: 32-6. Russian (Бутрова С.А., Ершова Е.В., Ильин А.В. и др. Адипонектин у мужчин с абдоминальным ожирением. Ожирение и метаболизм 2006; 2: 32-6).
16. Rothenbacher D, Brenner H, März W, et al. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 2005; 26 (16): 1640-6.
17. von Eynatten M, Hamann A, Twardella D, et al. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin Chem 2006; 52 (5): 853-9.
18. Verbovoy AF, Mitroshina EV, Dolgih YA. Adipokines, insulin resistance and the activity of the sympathoadrenal system in adolescents with puberty started obesity. Obesity and metabolism 2012; 2: 41-4. Russian (Вербовой А.Ф., Митрошина Е.В., Долгих Ю.А. Адипокины, инсулинорезистентность и активность симпато-адре- наловой системы у юношей с ожирением, манифестировавшим в пубертатный период. Ожирение и метаболизм 2012; 2: 41-4).
19. Jaleel A, Aheed B, Jaleel S, et al. Association of adipokines with obesity in children and adolescents. Biomark Med 2013; 7(5): 731-5.
20. Boyraz M, Cekmez F, Karaoğlu A, et al. Relationship of adipokines (adiponectin, resistin and RBP4) with metabolic syndrome components in pubertal obese children. Biomark Med 2013; 7(3): 423-8.
21. Lindberg S, Jensen JS, Bjerre M, et al. Adiponectin, type 2 diabetes and cardiovascular risk. Eur J Prev Cardiol 2013; http://www.ncbi.nlm.nih.gov/pubmed/?term=Lindberg +S%2C+Jensen+JS%2C+Bjerre+M+et+al.+Adiponectin%2C+type+2+diabetes+and +cardiovascular+risk (25 Nov 2013)
22. Lindberg S, Mogelvang R, Pedersen SH, et al. Relation of serum adiponectin levels to number of traditional atherosclerotic risk factors and all-cause mortality and major adverse cardiovascular events (from the Copenhagen City Heart Study). Am J Cardiol 2013; 111(8): 1139-45.
23. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291 (14): 1730-7.
24. Costacou T, Zgibor JC, Evans RW, et al. The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2005; 48 (1): 41-8.
25. Koenig W, Khuseyinova N, Baumert J, et al. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. JACC 2006; 48 (7): 1369-77.
26. Frystyk J, Berne C, Berglund L, et al. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 2007; 92 (2): 571-6.
27. Tao L, Gao E, Jiao X, et al. Adiponectin cardioprotection after myocardial ischemia/ reperfusion involves the reduction of oxidative/nitrative stress. Circulation 2007; 115 (11): 1408-16.
28. Wannamethee SG, Whincup PH, Lennon L, et al. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Archives of internal medicine 2007; 167 (14): 1510-7.
29. Dekker JM, Funahashi T, Nijpels G, et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clinical Endocrinol and Metabol 2008; 93 (4): 1489-96.
30. Singer JR, Palmas W, Teresi J, et al. Adiponectin and all-cause mortality in elderly people with type 2 diabetes. Diabetes Care 2012; 35(9): 1858-63.
31. Hung WC, Wang CP, Lu LF, et al. Circulating adiponectin level is associated with major adverse cardiovascular events in type 2 diabetic patients with coronary artery disease. Endocr J 2010; 57(9): 793-802.
32. Wannamethee SG, Welsh P, Whincup PH, et al. High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: does NT-proBNP help to explain this association? Eur J Cardiovas Prevent Rehabilit 2011; 18 (1): 65-71.
33. Bruce CR, Mertz VA, Heigenhauser GJ, et al. The stimulatory effect of globular adiponectin on insulin-stimulated glucose uptake and fatty acid oxidation is impaired in skeletal muscle from obese subjects. Diabetes 2005; 54 (11): 3154-60.
34. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002; 32 (3): 14-23.
35. Mullen KL, Pritchard J, Ritchie I, et al. Adiponectin resistance precedes the accumulation of skeletal muscle lipids and insulin resistance in high-fat-fed rats. Am J Physiol Regul Integr Comp Physiol 2009; 296 (2): R243-51.
36. Li R, Xu M, Wang X, et al. Reduced vascular responsiveness to adiponectin in hyperlipidemic rats--mechanisms and significance. J Mol Cell Cardiol 2010; 49 (3): 508-15.
37. Lau WB, Tao L, Wang Y, et al. Review Systemic adiponectin malfunction as a risk factor for cardiovascular disease. Antioxid Redox Signal 2011; 15(7): 1863-73.
38. van Berendoncks AM, Garnier A, Beckers P, et al. Functional adiponectin resistance at the level of the skeletal muscle in mild to moderate chronic heart failure. Circ Heart Fail. 2010; 3 (2): 185-94.
39. Antoniades C, Antonopoulos AS, Tousoulis D, et al. Adiponectin: from obesity to cardiovascular disease. Obes Rev 2009; 10 (3): 269-79.
40. Acharya SD, Brooks MM, Evans RW, et al. Weight loss is more important than the diet type in improving adiponectin levels among overweight/obese adults. J Am Coll Nutr 2013; 32 (4): 264-71.
41. Richard C, Royer MM, Couture P, et al. Effect of the Mediterranean diet on plasma adipokine concentrations in men with metabolic syndrome. Metabolism 2013; 62 (12): 1803-10.
42. Shrestha C, He H, Liu Y, et al. Changes in Adipokines following Laparoscopic Rouxen-Y Gastric Bypass Surgery in Chinese Individuals with Type 2 Diabetes Mellitus and BMI of 22-30kg•m(-2.). Int J Endocrinol. 2013; 2013: ID 240971.
43. Hindle AK, Edwards C, McCaffrey T, et al. Reactivation of adiponectin expression in obese patients after bariatric surgery. Surg Endosc Other Intervent Techniq 2010; 24 (6): 1367-73.
44. Whitson BA, Leslie DB, Kellogg TA, et al. Adipokine response in diabetics and nondiabetics following the roux-en-Y gastric bypass: a preliminary study. J Surgl Res 2007; 142 (2): 295-300.
45. Illán-Gómez F, Gonzálvez-Ortega M, Orea-Soler I, et al. Obesity and inflammation: change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. Obesity Surgery 2012; 22 (6): 950-5.
46. Vendrell J, Broch M, Vilarrasa N, et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 2004; 12 (6): 962-71.
47. Zhang W, Wu R, Zhang F, et al. Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway. Clin Exp Pharmacol Physiol 2012; 39 (12): 1026-33.
48. McCoy RG, Irving BA, Soop M, et al. Effect of insulin sensitizer therapy on atherothrombotic and inflammatory profiles associated with insulin resistance. Mayo Clin Proc 2012; 87 (6): 561-70.
49. Gealekman O, Guseva N, Gurav K, et al. Effect of rosiglitazone on capillary density and angiogenesis in adipose tissue of normoglycaemic humans in a randomised controlled trial. Diabetologia 2012; 55 (10): 2794-9.
50. Okada-Iwabu M, Yamauchi T, Iwabu M, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 2013; 503 (7477): 493-9.
Рецензия
Для цитирования:
Митрошина Е.В., Вербовой А.Ф. МЕТАБОЛИЧЕСКИЕ ЭФФЕКТЫ АДИПОНЕКТИНА. Кардиоваскулярная терапия и профилактика. 2014;13(6):68-72. https://doi.org/10.15829/1728-8800-2014-6-68-72
For citation:
Mitroshina E.V., Verbovoy A.F. METABOLIC EFFECTS OF ADIPONECTINE. Cardiovascular Therapy and Prevention. 2014;13(6):68-72. (In Russ.) https://doi.org/10.15829/1728-8800-2014-6-68-72
Просмотров:
936
Послать статью по эл. почте 
